Canadian trial suggests high-dose vitamin B3 may strengthen glioblastoma treatment

Canada is emerging as a focal point in the search for new treatments for glioblastoma, one of the most aggressive and difficult-to-treat forms of brain cancer. Researchers at the University of Calgary have reported encouraging early results from a clinical trial investigating whether high-dose vitamin B3, known as niacin, can enhance standard treatment by reviving the body’s immune response against the disease. The findings are significant not only because glioblastoma survival rates have changed little over the past two decades, but also because the work highlights the growing contribution of Canadian research institutions to the development of novel cancer therapies. Conducted through Calgary’s Hotchkiss Brain Institute and Arnie Charbonneau Cancer Institute, the study is exploring an unconventional strategy that could eventually complement surgery, radiotherapy and chemotherapy.

According to interim results published in the Journal of Neuro-Oncology, 82% of participants remained free from disease progression six months after treatment. For a cancer where therapeutic advances have been rare, the findings offer a welcome signal that a new avenue may be worth pursuing.

Glioblastoma affects thousands of people across North America each year and remains one of the most feared cancer diagnoses. Current treatments can slow tumour growth, but recurrence is common and long-term survival remains limited. Canadian researchers have increasingly focused on developing innovative therapies that work with the body’s own biology rather than simply targeting tumour cells directly. The Calgary team’s niacin study reflects this trend, building on years of laboratory research conducted within Canada’s publicly funded research environment. The trial is being led by neuro-oncologist Dr Gloria Roldan Urgoiti and neuroscientist Dr Wee Yong, both affiliated with some of Canada’s leading neuroscience and cancer research centres. Their work addresses a key feature of glioblastoma: its ability to cripple immune cells that would otherwise help destroy cancerous tissue. Rather than attacking the tumour directly, the researchers are attempting to restore the immune system’s natural capacity to recognise and combat the disease.

From Calgary laboratories to patient care

The concept originated in pre-clinical studies carried out in Yong’s laboratory, where experiments suggested that niacin could improve survival in animal models of glioblastoma. Those findings provided sufficient evidence to launch a combined Phase I and Phase II clinical trial involving patients receiving conventional treatment. The study represents an example of translational research, where discoveries made in Canadian laboratories are rapidly assessed in clinical settings. For participant Edward Waldner, joining the study offered something that many glioblastoma patients desperately seek: an additional opportunity to fight the disease. Following surgery, Waldner was invited to participate in the trial and agreed immediately.

His experience highlights a broader challenge facing Canadian cancer care. Despite advances in many tumour types, glioblastoma remains an area where patients and clinicians continue searching for better options. Clinical trials therefore play a crucial role within Canada’s healthcare system, providing access to experimental approaches while generating evidence that may benefit future patients.

Researchers believe niacin may help counter one of glioblastoma‘s most effective survival mechanisms. The tumour creates an environment that suppresses immune activity, effectively disarming some of the body’s natural defences. The Calgary team found evidence suggesting that high-dose niacin can rejuvenate these weakened immune cells, potentially restoring their ability to attack cancer cells. This approach aligns with broader international efforts to harness the immune system against cancer. Immunotherapies have transformed outcomes for several cancers over the past decade, although glioblastoma has proven particularly resistant to many existing immune-based treatments. If niacin can successfully shift the balance back towards immune activation, it could provide a relatively straightforward addition to existing treatment protocols.

Importantly, researchers are taking a cautious view of the results. The current analysis covers only 24 patients, making the study too small to draw definitive conclusions. Early-stage clinical trials are designed primarily to assess safety and identify potential signals of effectiveness rather than establish a new standard of care. Nevertheless, the results exceeded expectations. Researchers had established a minimum threshold that would justify continuation of the trial. The observed progression-free survival rate surpassed that benchmark, encouraging the team to proceed with further enrolment and analysis.

The study ultimately aims to recruit 48 participants before a final assessment is undertaken. For Canada’s cancer research community, the findings provide another example of how investigator-led studies can generate promising therapeutic leads even in areas where pharmaceutical innovation has been limited.

A reminder that vitamins can act like medicines

One important message emerging from the research is that patients should not attempt to self-medicate with high doses of niacin. Although vitamin B3 is readily available in supplements and occurs naturally in foods, the quantities used in the trial are being carefully monitored under medical supervision. High doses can produce adverse effects, including liver-related complications and other toxicities. Researchers therefore stress that the treatment being studied should be viewed as a controlled medical intervention rather than a nutritional supplement. The distinction is particularly important as interest grows in the potential role of vitamins and metabolic therapies in cancer treatment.

What comes next?

The Calgary team expects to complete its final analysis after the remaining participants have been enrolled and followed. Only then will researchers be able to determine whether the apparent improvement translates into meaningful gains in overall survival and long-term outcomes. If successful, the study could pave the way for larger multicentre investigations involving cancer centres across Canada and internationally. For now, the research remains an encouraging development rather than a confirmed breakthrough. Yet in a disease where progress has been painfully slow, even incremental advances matter.

Perhaps most importantly, the study demonstrates how Canadian researchers are contributing to global efforts to tackle some of medicine’s most difficult challenges. From laboratory discoveries in Calgary to patients receiving treatment within the Canadian healthcare system, the project showcases the country’s capacity to generate innovative, clinically relevant cancer research. For patients such as Waldner, the hope is simple: that one day “stable” may be joined by longer survival and better outcomes. For Canada’s scientific community, the trial represents another step towards turning that hope into evidence-based reality.